+158.1%
DASH vs MRNA
+35.3%
+122.9%
-48.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.6% | -2.2% | -2.4% | -4.5% |
| 7D | -10.6% | +5.5% | -16.0% | -10.8% |
| 30D | +2.2% | +158.7% | -156.6% | -5.5% |
| 3M | +32.3% | +182.1% | -149.9% | +20.8% |
| 6M | +19.1% | +151.8% | -132.7% | +9.7% |
| YTD | -6.5% | +393.6% | -400.1% | -19.6% |
| 1Y | -14.9% | +499.5% | -514.4% | -28.5% |
| All | +158.1% | +35.3% | +122.9% | +121.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling